title: Immunoexpression and prognostic role of p53 in different subtypes of epithelial ovarian carcinoma.
abstract: We sought to investigate the significance of p53 expression for epithelial ovarian carcinoma. In this study, we used immunohistochemical method to investigate the expression patterns of p53 in different subtypes of epithelial ovarian carcinoma. We found that the expressions of p53 protein in epithelial ovarian cancer (pituita, serosity and intima) were 88.9%, 75% and 100%, respectively, while the recurrence rates among three cancer subtypes were significantly different (33.3%, 12.5% and 0%, respectively; P < 0.05). Compared with patients without lymph node metastasis, the expression of p53 in patients with lymph node metastasis was significantly strong (68.75% and 100%, respectively; P < 0.05). However, the recurrence rate in the patients with lymph node metastasis (40%) was higher than that without lymph node metastasis (6.25%, P < 0.05). The expressions of p53 protein in ovarian cancer between I-II (25%) stage and II-IV stage (100%) were significantly different (P < 0.05), and the recurrence rates between the two groups were significantly different (0% and 31.25%, respectively, P < 0.05). Therefore, p53 protein has an intimate relationship with the malignant degree and the prognosis of ovarian cancer.
authors.affiliation: Department of Cancer Research/Key Laboratory of Environment and Gene Related to Diseases of Ministry of Education, Xi'an Jiaotong University, School of Medicine, Xi'an, Shaanxi 710061, China; ; Department of Gynecology and Obstetrics, Shaanxi Provincial People's Hospital, Xi'an, Shaanxi 710068, China;
authors.forename: Lihong
authors.initials: L
authors.lastname: Chen
authors.forename: Lianxiang
authors.initials: L
authors.lastname: Li
authors.forename: Feng
authors.initials: F
authors.lastname: Chen
authors.forename: Dalin
authors.initials: D
authors.lastname: He
keywords: ovarian cancer; p53; prognosis
references.citation: Mol Carcinog. 2002 Jun;34(2):78-90
references.pmid: 12112314
references.citation: Int J Surg Pathol. 2007 Oct;15(4):335-45
references.pmid: 17913939
references.citation: Surg Oncol Clin N Am. 2002 Jul;11(3):521-35
references.pmid: 12487055
references.citation: Am J Pathol. 2002 Jun;160(6):2181-90
references.pmid: 12057921
references.citation: Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):246-51
references.pmid: 20018721
references.citation: Nat Rev Cancer. 2009 Oct;9(10):701-13
references.pmid: 19693097
references.citation: Ann Oncol. 2003 Jul;14(7):1078-85
references.pmid: 12853350
references.citation: CA Cancer J Clin. 2011 May-Jun;61(3):183-203
references.pmid: 21521830
references.citation: Eur J Gynaecol Oncol. 2010;31(3):268-77
references.pmid: 21077467
references.citation: J Cell Biol. 2011 Jan 24;192(2):209-18
references.pmid: 21263025
references.citation: Int J Oncol. 2012 Jun;40(6):1865-80
references.pmid: 22344671
references.citation: Nat Genet. 2001 Dec;29(4):418-25
references.pmid: 11694875
references.citation: Cell Death Differ. 2011 Feb;18(2):271-81
references.pmid: 20689556
references.citation: Am J Dermatopathol. 2012 Apr;34(2):129-35; quiz 136-8
references.pmid: 22441365
references.citation: Br J Cancer. 2011 Nov 8;105(10):1593-9
references.pmid: 22009029
references.citation: Gynecol Oncol. 2002 Mar;84(3):399-403
references.pmid: 11855877
references.citation: Adv Med Sci. 2012 Jun 1;57(1):77-83
references.pmid: 22440942
references.citation: Int J Gynecol Cancer. 2008 Sep-Oct;18(5):963-75
references.pmid: 18028382
references.citation: Cancer Res. 2003 Jul 1;63(13):3459-63
references.pmid: 12839925
references.citation: Crit Rev Clin Lab Sci. 2004;41(5-6):551-83
references.pmid: 15603511
references.citation: Science. 1991 Jul 5;253(5015):49-53
references.pmid: 1905840
references.citation: Am J Pathol. 2004 Aug;165(2):397-414
references.pmid: 15277215
references.citation: Cell Cycle. 2012 Apr 15;11(8):1564-72
references.pmid: 22433954